Supplementary Information for

Glycocalyx Engineering Reveals a Siglec-Based Mechanism for NK Cell Immunoevasion

Jason E. Hudak, Stephen M. Canham, Carolyn R. Bertozzi

Departments of Chemistry, Molecular and Cellular Biology, Howard Hughes Medical Institute, University of California, Berkeley, California, 94720
Supplementary Results

Supplementary Figure 1. AF488 labeled glycopolymers can incorporate a wide range of glycan structures into a variety of cell types

(a) Fluorescence microscopy of Chinese Hamster Ovary (CHO) cells treated with Alexa Fluor 488 (AF488) or biotin conjugated polymers. Biotin was further labeled by treatment with anti-biotin-488. Scale bars, 10 µm. (b) MCF-7 breast cancer cells show labeling with 2,6-SiaLacNAc polymer (left panel) while 2,6-SiaLacNAc polymers without the phospholipid tail do not incorporate well (right panel). Scale bars, 100 µm. (c) Fluorescence microscopy of sialic acid and GD3 AF488 conjugated polymers on prostate cancer DU145 cells and myelogenous leukemia K562 cells. Scale bars, 10 µm.
Supplementary Figure 2. Cell density and glycan structure have minor influence on glycopolymer incorporation

(a) Jurkat cells at 10^6 or 10^7 cells/mL were incubated with 0, 0.1, or 1 µM AF488-Lac polymer at room temperature in MEM for 1 h. Cells were washed with 1% FBS in PBS and analyzed by flow cytometry. (b) Jurkat cells at 10^7 cells/mL were incubated with 0.5 µM of the indicated AF488 labeled polymer at room temperature in HBSS for 45 min.
Supplementary Figure 3. Half-life of glycopolymers on Jurkat cell surfaces

Jurkat cells were incubated with 1 µM (a) biotin-GalNAc polymer or (b) biotin-Lac polymer at room temperature in HBSS for 45 min. Cells were washed and cultured in RPMI-1640 supplemented with 10% FBS. An aliquot of 7 × 10^5 cells were removed at the indicated time and washed with cold 1% FBS in PBS. Cells were labeled with 1/100 anti-biotin 647 in 1% FBS in PBS for 20 min on ice. Cells were washed and analyzed by flow cytometry. Experiments were performed in triplicate and half lifes were calculated by best fit to the equation \( x = x_0 e^{kt} \) in MATLAB.

Supplementary Figure 4. Glycopolymers are accessible to lectin binding

Binding of SNA-FITC or Siglec-7-hFc to Jurkat cells after incubation with 1 µm 2,6-SiaLacNAc polymer was assessed by flow cytometry. Data are presented as mean ± s.d. from three independent experiments.
Supplementary Figure 5. Glycopolymers protect target cells from PBMC derived NK-mediated cytotoxicity in a structure dependent manner

Jurkat cells were labeled with 1 \( \mu \text{M} \) indicated polymer and incubated with PBMC at an effector to target ratio of 20:1 in a 4 h cytotoxicity assay. The best protection was seen with the Sia polymer while other sialylated ligands provided reduced though still significant inhibition.

Supplementary Figure 6. Glycopolymer protection from purified NK cell cytotoxicity

Jurkat cells were incubated with 1 \( \mu \text{M} \) polymer for 45 min at room temperature and mixed with purified NK cells at indicated effector to target ratios. The coculture was incubated for 4 h at 37 \( ^\circ \text{C} \) in 5\% \( \text{CO}_2 \) and cell death was quantified by propidium iodide staining in flow cytometry.
Supplementary Figure 7. Binding of soluble Siglec-9-Fc to cell surface glycopolymers

Jurkat cells were treated with indicated polymer and Siglec-9-Fc binding was assessed by labeling with secondary anti-humanFc-647 followed by flow cytometry.
Supplementary Figure 8. Siglec expression on purified human NK cells

(a) Purified human NK cells show ubiquitous Siglec-7 expression at high levels across several donors. (b) Siglec-9 is expressed at lower levels and only in a subset of human NK cells. Cells were phenotyped after isolation from fresh human PBMC by labeling with the indicated antibody and analysis by flow cytometry. Axes are labeled with the indicated marker or by channel (e.g. FL1-H) is no marker was present.
**Supplementary Figure 9.** Artificially crosslinking Siglec-7 does not affect cytotoxicity

NK cells were incubated with 10 µg/mL of anti-Siglec-7 (6-434, non-function blocking) or isotype antibody at rt for 20 min. followed by addition of 20 µg/mL of goat anti-Ms F(ab')2. NK cells with crosslinked Siglec-7 were then cocultured with K562 cells at the indicated effector:target ratios for 4 h and analyzed for cytotoxicity by flow cytometry. As shown, Siglec-7 crosslinking alone did not alter the NK cytotoxic profile.

**Supplementary Figure 10.** Siglec-7 overexpression promotes Sia polymer inhibition

NK-92 cells overexpressing Siglec-7 showed inhibited cytotoxicity against Sia polymer coated Jurkat cells. Mock treated or Siglec-9 overexpressing cells show insignificant difference in killing, though killing was overall depressed with Siglec-9 overexpression. Data are presented as mean ± s.d. from three independent experiments (*P < 0.05, **P < 0.01 for polymer coated versus no polymer control, two-tailed, paired analysis; n.s. not significant).
Removal of cell surface sialic acid from WiDr colon, HepG2 hepatocarcinoma, Jurkat T lymphoma and H9 cutaneous T lymphoma cell lines increases susceptibility to NK cell cytotoxicity and is recovered by treatment with the sialic acid polymer (SiaPol). Cancer target cells were treated with VC sialidase for 1 h at 37 °C before polymer incorporation at room temperature and coculture with purified NK (5:1, effector:target) in a 4 h cytotoxicity assay. Data are presented as mean ± s.e.m. from three independent experiments (*P < 0.05, **P < 0.01, for polymer coated versus no polymer control, two-tailed, paired analysis).
Supplementary Figure 12. Glycopolymers recover sialylation-based protection in a structure dependent manner

(a) Jurkat or (b) HL-60 cells were treated with VC sialidase for 1.5 h at 37 °C and labeled with 1 µM indicated polymer before coculture with primary NK cells at a (a) 3:1 or (b) 5:1 effector to target ratio. Interestingly, the GD3 polymer protected well on HL-60 cells that were sialidase treated but only moderately on Jurkat cells possibly due to a cell type dependent difference in polymer loading after sialidase treatment.
Supplementary Figure 13. Sialylation status of target cell correlates with Siglec-7 phosphorylation and SHP-1 recruitment

Western blot analysis of NK-92 or primary NK cells stimulated with target cells treated with sialidase and coated with Sia polymer. (a) Colon HT-29, or (b) breast MCF-7 cell lines were cocultured with NK-92 cells overexpressing Siglec-7 at a 2:1 effector to target ratio and lysed immediately or at 5 min. Immunoprecipitation with anti-FLAG M2 agarose beads was used to isolate Siglec-7 before SDS-PAGE and immunoblot analysis. (c) HT-29 cells were treated as in (a) but cocultured with primary NK cells and immunoprecipitated with anti-Siglec-7 antibody. Sialidase treatment of the target cancer cell decreased Siglec-7 phosphorylation in all cases which was recovered by coating with the Sia polymer.
Supplementary Figure 14. Blocking Siglec-7 abrogates sialic acid dependent protection from NK cell cytotoxicity

Purified NK cells were preincubated with 10 µg/mL of Siglec-7-blocking or isotype antibody and mixed with HL-60 cells at a 5:1 NK cell to target ratio in a 4 h cytotoxicity assay. The Siglec-7 blocking antibody significantly decreased the effects of sialidase and polymer treatment (**P < 0.01, for sialidase treated versus no treatment control or Sia polymer coated versus sialidase treated, two-tailed, paired analysis; n.s. not significant).

Supplementary Figure 15. Siglec-7 expression is necessary for sialic acid dependent protection from NK-92 cell killing

NK-92 cells overexpressing FLAG-tagged Siglec-7 were cocultured with HL-60 cells at an 8:1 NK cell to target ratio. Only NK-92 cells expressing Siglec-7 were susceptible to sialylation dependent inhibition while mock treated cells were not affected (**P < 0.01, for sialidase treated versus no treatment control or Sia polymer coated versus sialidase treated, two-tailed, paired analysis; n.s. not significant).
Cell surface sialic acid could also dampen NK-mediated ADCC against SK-BR-3 breast adenocarcinoma cells. Cytotoxicity assays were performed in the presence of 2 µg/mL anti-HER2 antibody in increasing NK:target ratios. Data are presented as mean ± s.d. from three independent experiments (*$P < 0.05$, **$P < 0.01$ for polymer coated versus no polymer control, two-tailed, paired analysis).
Supplementary Note 1

Additional Synthetic Methods

General materials

Synthetic reagents were purchased from Sigma-Aldrich, Acros, and TCI and used without purification unless noted otherwise. Anhydrous DMF and MeOH, 99.9% purity were purchased from Acros in sealed bottles; all other anhydrous solvents (Fisher brand; HPLC grade) were obtained from an alumina column solvent purification system. EZ-Link Alkoxysamine-PEG4-Biotin (AO-biotin) was purchased from Pierce/Thermo Scientific. All reactions were carried out in flame-dried glassware under N₂ unless otherwise noted. In all cases, solvent was removed by reduced pressure with a Buchi Rotovapor R-114 equipped with a Welch self-cleaning dry vacuum. Products were further dried by reduced pressure with an Edwards RV3 high vacuum. Lyophilization was performed on a LABCONCO FreeZone instrument equipped with an Edwards RV2 pump. Thin layer chromatography was performed using Silicycle 60 Å silica gel plates and detected by UV lamp or charring with p-anisaldehyde in acidic EtOH. Flash chromatography was performed using Silicycle 60 Å 230-400 mesh silica. All ¹H and ¹³C NMR spectra are reported in ppm and referenced to solvent peaks. NMR spectra were obtained from the UC Berkeley Mass Spectrometry Facility using an LTQ Orbitrap (Thermo Fisher Scientific).

Synthetic procedures and analytical data for new aminooxy compounds.

Aminooxy 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate (11).

To the known protected precursor³ O-[Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonate] N-hydroxysuccinimide (210 mg, 0.36 mmol) in 4 mL anhydrous MeOH was added hydrazine hydrate (26 µL, 0.54 mmol) dropwise at 4 °C and warmed to room temperature over 4 h. The reaction mixture was diluted with CH₂Cl₂ and concentrated under reduced pressure. The crude residue was purified by silica chromatography (1%-20% MeOH/CH₂Cl₂) to give the protected neuraminic acid with the free aminooxy (117 mg, 64%). The intermediate was dissolved in 3 mL anhydrous MeOH and NaOMe (25% in MeOH, 103 µL) was added dropwise while stirring at rt for 1 h followed by the addition of NaOH (1 M, 300 µL). After an additional 1 h, the reaction was neutralized with AcOH and stirred overnight at room temperature to complete hydrolysis. The resulting product was concentrated under vacuum and purified by silica column chromatography (4:2:1 EtOAc/MeOH/H₂O). The desired fractions were pooled and concentrated under vacuum. The purified product was then dissolved in ddH₂O and lyophilized to give the free aminooxy sialic acid 11 (49 mg, 65%) as an off-white powder.¹H NMR (600 MHz, D₂O) δ 3.92 – 3.75 (m, 4H), 3.70 – 3.65 (m, 1H), 3.59 (dt, J = 17.7, 8.8 Hz, 1H), 3.53 (d, J = 9.0 Hz, 1H), 2.57 (dd, J = 12.6, 4.8 Hz, 1H), 2.00 (s, 3H), 1.68 (t, J = 12.1 Hz, 1H); ¹³C NMR (151 MHz, D₂O) δ 174.99, 173.47, 103.16, 72.80, 71.38, 68.23, 68.09, 62.73, 51.78, 37.93, 22.00; HRMS (ESI): calcd for C₁₁H₂₀N₂O₉ [M+H]⁺ m/z = 325.1242, found: 325.1253.
N-hydroxypent-4-eneamide \((5\text{-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosylonic acid)-(2→8)-α-(5\text{-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosylonic acid)-(2→3)-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (12).\)}

\(N\)-Pentenoyl aminoxy 2,3-sialyllactose\(^4\) (19 mg, 0.025 mmol), \(N\)-acetyl mannosamine (8.4 mg, 0.038 mmol), sodium pyruvate (14 mg, 0.127 mmol), and CTP•Na (21 mg, 0.038 mmol) were combined and dissolved in \(H_2O\) (3 mL). A concentrated stock of Tris-HCl buffer pH 8.5 with MgCl\(_2\) was added to a final concentration of 100 mM Tris, 20 mM MgCl\(_2\). Recombinant \(E.\ coli\) K12 sialic acid aldolase (2.5 U), \(N.\ meningitidis\) CMP-sialic acid synthetase (2.5 U), and \(C.\ jejuni\) α-2,8-sialyltransferase CstII (3 U) were added followed by \(H_2O\) to bring the volume to 4 mL. The reaction mixture was incubated at 37 °C for 4 h followed by shaking at rt for 16 h. The reaction was monitored by TLC (4:2:1 EtOAc/MeOH/H\(_2\)O) until the solution became clear. The solvent was removed and the residue was passed through a BioGel P-2 size exclusion column and lyophilized to give the free aminoxy glycoside 12 (22 mg, 85%) as a white, fluffy powder after lyophilization. \(^1\)H NMR (500 MHz, \(D_2O\)) δ 5.79 (dq, \(J = 10.4, 6.4\) Hz, 1H), 5.03 (dd, \(J = 21.9, 13.7\) Hz, 2H), 4.66 (d, \(J = 8.1\) Hz, 1H), 4.48 (d, \(J = 7.9\) Hz, 1H), 4.12 (dd, \(J = 12.2, 3.2\) Hz, 1H), 4.08 – 3.99 (m, 2H), 3.99 – 3.88 (m, 2H), 3.86 – 3.75 (m, 7H), 3.73 – 3.66 (m, 5H), 3.64 – 3.50 (m, 9H), 3.43 (t, \(J = 8.7\) Hz, 1H), 2.74 (dd, \(J = 12.4, 4.5\) Hz, 1H), 2.62 (dd, \(J = 12.3, 4.3\) Hz, 1H), 2.36 – 2.22 (m, 4H), 2.02 (s, 3H), 1.98 (s, 3H), 1.71 (q, \(J = 11.7\) Hz, 2H); \(^13\)C NMR (151 MHz, \(D_2O\)) δ 174.91, 173.41, 173.27, 172.63, 163.34, 115.95, 105.10, 102.58, 100.45, 100.09, 78.14, 77.27, 75.38, 75.15, 74.99, 73.95, 72.58, 71.67, 70.94, 69.19, 68.41, 68.04, 67.83, 67.37, 62.47, 61.47, 61.36, 61.03, 59.67, 59.24, 52.19, 51.66, 40.42, 39.62, 31.63, 28.86, 22.23, 21.96; HRMS (ESI): calcd for \(C_{39}H_{62}N_3O_{28}\) [M-H]+ \(m/z = 1020.3525\), found: 1020.3520.

Aminoxy (5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→8)-α-(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→3)-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (GD3) (13). A solution of \(N\)-pentenoyl aminoxy sialoside 12 (13 mg, 0.013 mmol) in \(H_2O/MeCN/MeOH/FA \ (1:1:1:0.001, v:v:v\) 1.2 mL) was stirred at rt with dropwise addition of I\(_2\) (0.064 mmol, 1 M solution in THF). After 1 h, MeONH\(_2\) (53 mg, 0.64 mmol) was added to ensure complete deprotection and heated to 38 °C for 2 h after which the reaction was quenched by the addition of 50 mM Na\(_2\)S\(_2\)O\(_3\) in \(H_2O\) until the solution became clear. The solvent was removed and the remaining residue was passed through a short silica chromatography column (EtOAc/MeOH/H\(_2\)O). The desired fractions were pooled and concentrated. The material was further purified on a BioGel P-2 size exclusion column and lyophilized to give the free aminoxy GD3 (13) (7.5 mg, 63%) as a white powder. \(^1\)H NMR (500 MHz, \(D_2O\)) δ 4.56 (d, \(J = 8.2\) Hz, 1H), 4.48 (d, \(J = 6.4\) Hz, 1H), 4.21 – 4.01 (m, 3H), 4.01 – 3.89 (m, 2H), 3.89 – 3.73 (m, 7H), 3.69 – 3.48 (m, 13H), 3.31 (t, \(J = 8.5\) Hz, 1H), 2.74 (d, \(J = 8.1\) Hz, 1H), 2.64 (d, \(J = 12.2\) Hz, 1H), 2.02 (s, 3H), 1.99 (s, 3H), 1.70 (t, \(J = 12.0\) Hz, 2H); \(^13\)C NMR (126 MHz, \(CDCl_3\)) δ 174.94, 173.10, 108.80, 104.55, 102.60, 99.91, 98.38, 77.87, 75.81, 75.64, 75.31, 74.34, 74.21, 73.96, 73.89, 73.62, 72.66, 72.50, 71.71, 71.50, 71.28, 69.87, 69.24, 68.95, 68.35, 68.09, 68.02, 67.97, 67.81, 62.80, 62.50, 62.31, 61.05, 60.26, 59.84, 58.73, 52.10, 52.00, 51.66, 46.79, 43.25, 40.52, 32.41, 22.21, 22.02, 21.97; HRMS (ESI): calcd for \(C_{34}H_{57}N_3O_{27}\) [M-2H]+ \(m/z = 468.6517\), found: 468.6526.
3-aminooxy-1,2-propanediol (14). N-hydroxyphthalimide (160 mg, 0.97 mmol) and KCO$_3$ (402 mg, 12.9 mmol) were suspended in 10 mL anhydrous DMF. 3-bromo-1,2-propanediol (170 µL, 1.94 mmol) was added to the suspension and heated at 60 °C for 18 h. The reaction was diluted with H$_2$O and extracted with CH$_2$Cl$_2$. The combined organic layers were dried over Na$_2$SO$_4$, filtered and concentrated under vacuum. The residue was purified by silica column chromatography (Hex/EtOAc) to afford the phthalimide protected aminooxy glycerol (72 mg, 16%). The product was dissolved in 2 mL anhydrous MeOH and hydrazine hydrate (16 µL, 0.33 mmol) was added dropwise with stirring at room temperature. After 2 h, the mixture was dissolved in MeOH, filtered and concentrated under vacuum. The reaction mixture was purified by silica chromatography (10%–20% MeOH in EtOAc) and the fractions were pooled and concentrated. The product was dissolved in ddH$_2$O and lyophilized to yield the aminooxy glycerol product (24 mg, 83%).

$^1$H NMR (500 MHz, D$_2$O) δ 3.94 – 3.87 (m, 1H), 3.76 (dd, $J$ = 10.9, 3.7 Hz, 1H), 3.68 (dd, $J$ = 10.9, 7.2 Hz, 1H), 3.60 (dd, $J$ = 11.8, 4.4 Hz, 1H), 3.52 (dd, $J$ = 11.8, 6.2 Hz, 1H); $^{13}$C NMR (151 MHz, D$_2$O) δ 76.35, 69.53, 62.53; HRMS (ESI): calcd for C$_3$H$_9$N$_1$O$_3$ [M+H]$^+$ m/z = 108.0655, found: 108.0654.

Synthetic procedures and analytical data for glycopolymers.

Dipalmitoylphosphatidylethanolamine-poly(methyl vinyl ketone) (DPPE-PolyMVK) (1). DPPE-Poly(MVK) was synthesized as previously described.$^{51}$ N,N-diisopropylethylamine (15 µL, 0.070 mmol) and the pentafluorophenyl activated ester of 4,4'‐azobis(4-cyanovaleric acid) (ACVA‐PFP)$^{51}$ (15 mg, 0.016 mmol) were added to a solution of DPPE (40 mg, 0.036 mmol) in MeOH (1.5 mL) and CHCl$_3$ (3.5 mL). After stirring at room temperature for 2 h, the resulting phospholipid initiator was concentrated by rotary evaporation. The resulting oil was suspended in anhydrous toluene (750 µL) and methyl vinyl ketone (210  µL, 2.5 mmol) was added followed by degassing with four freeze-pump-thaw cycles. The solution was heated to 80 ºC for 20 h and upon cooling to room temperature the polymer product was dissolved in minimal p-dioxane (3 mL) and triturated by dropwise addition to excess diethyl ether (300 mL). The precipitate was isolated by centrifugation (3,700×g, 20 min), washed with diethyl ether, and dried under vacuum to afford DPPE-PolyMVK as an off-white solid (110 mg). Spectral properties matched those previously reported.$^{51}$ $^1$H NMR (500 MHz, CHCl$_3$) δ 4.20 (app t, 2H), 3.78 (app t, 2H), 3.68 – 3.65 (m, 11H), 3.44 (app t, 2H); SEC (DMF, polystyrene standard): $M_w$ = 26 × 10$^3$ Da, PDI = 2.89.

Aminooxy Glycan-Conjugated Polymers.

All aminooxy compounds were conjugated to the DPPE-PolyMVK backbone by the following method: A mixture of 1 (1 equiv.), aminooxy compound (1.4 equiv. to ketone), and formic acid (1% v/v) in MeCN/MeOH (2:1, v/v) was stirred at 50 °C for 20 h. To the reaction mixture was added H$_2$O (to 25% v/v) and stirring was continued at 32 °C for 18 h. For biotin and AF488 labeling, AO-biotin and AO-AF488 were added to the initial reaction mixture at 0.01 equivalents. After completion, the reaction was diluted in H$_2$O and MeOH and concentrated under vacuum. The resulting residue was dissolved in H$_2$O and dialyzed against aqueous 5mM NH$_4$HCO$_3$ thrice and H$_2$O once over 72 h to afford the corresponding oxime phospholipid polymer after lyophilization. Conversion was estimated by comparing the integration
N-acetylneuraminic acid (Sia) MVK polymer (2). Polymer 2 was given from reaction of polymer 1 with aminooxy sialic acid 11 as an off-white solid (1.7 mg, 55%). Conversion (NMR) = 0.69; Mₙ (NMR) = 114 kDa; ¹H NMR (500 MHz, D₂O) δ 3.99 – 3.36 (m, 7H), 3.01 – 2.81 (m, 1H), 2.77 – 2.40 (m, 3H), 2.00 (s, 4H), 2.37 – 0.55 (m, 9H), 1.81 – 1.74 (m, 1H).

N-acetylneuraminic acid-α2,6-galactose-β1,4-N-acetylgalactosamine (2,6-SiaLacNAc) MVK polymer (3). Polymer 1 was reacted with aminooxy 2,6SiaLacNAc⁴ to give polymer 3 as a white solid (2 mg, 61%). Conversion (NMR) = 0.84; Mₙ (NMR) = 256 kDa; ¹H NMR (500 MHz, D₂O) δ 5.11 – 4.85 (m, 1H), 4.78 – 4.72 (m, 1H), 4.55 – 4.31 (m, 1H), 4.20 – 2.95 (m, 16H), 2.73 – 2.52 (m, 1H), 2.00 (s, 6H), 1.75 – 1.70 (m, 1H), 2.31 – 0.56 (m, 7H).

N-acetylneuraminic acid-α2,3-galactose-β1,4-N-acetylgalactosamine (2,3-SiaLacNAc) MVK polymer (4). Polymer 1 was reacted with aminooxy 2,3SiaLacNAc⁴ to give polymer 4 as a white solid (2 mg, 49%). Conversion (NMR) = 0.73; Mₙ (NMR) = 222 kDa; ¹H NMR (500 MHz, D₂O) δ 5.04 – 4.86 (m, 1H), 4.77 – 4.33 (m, 2H), 4.23 – 3.09 (m, 14H), 2.73 (d, J = 5.2 Hz, 1H), 2.22 – 1.84 (m, 5H), 2.30 – 0.66 (m, 8H), 1.72 – 1.65 (m, 1H).

Galactose-β1,4-glucose (Lactose) MVK polymer (5). Aminooxy lactose⁴ was conjugated to polymer 1 to afford polymer 5 as a white solid (3.2 mg, 60%). Conversion (NMR) = 0.67; Mₙ (NMR) = 121 kDa; ¹H NMR (500 MHz, D₂O) δ 5.07 – 4.82 (m, 1H), 4.56 – 4.31 (m, 1H), 4.15 – 3.02 (m, 12H), 2.49 – 0.72 (m, 9H).

N-acetylgalactosamine (GalNAc) MVK polymer (6). Aminooxy GalNAc⁵ was conjugated to polymer 1 to afford polymer 6 as a white solid (1.7 mg, 46%). Conversion (NMR) = 0.65; Mₙ (NMR) = 80 kDa; ¹H NMR (500 MHz, D₂O) δ 5.32 (d, J = 26.8 Hz, 1H), 4.36 – 4.13 (m, 1H), 4.13 – 3.43 (m, 5H), 2.03 (s, 3H), 2.39 – 0.96 (m, 9H).

N-acetylneuraminic acid-α2,8-N-acetylneuraminic acid-α2,3-galactose-β1,4-glucose (GD3) MVK polymer (7). Polymer 7 was given from reaction of polymer 1 with aminooxy GD3 13 as a white solid (4.3 mg, 74%). Conversion (NMR) = 0.85; Mₙ (NMR) = 323 kDa; ¹H NMR (500 MHz, D₂O) δ 4.55 – 4.41 (m, 1H), 4.18 – 3.38 (m, 28H), 2.74 (d, J = 9.1 Hz, 1H), 2.62 (d, J = 11.6 Hz, 1H), 2.02 (s, 6H), 2.48 – 0.66 (m, 7H), 1.75 – 1.67 (m, 2H).

N-acetylneuraminic acid-α2,3-galactose-β1,4-(α1,3-fucose)-N-acetylgalactosamine (SiaLe⁴) MVK polymer (8). Polymer 1 was reacted with aminooxy SiaLe⁵ to give polymer 8 as a white solid (2.6 mg, 59%). Conversion (NMR) = 0.75; Mₙ (NMR) = 275 kDa; ¹H NMR (500 MHz, D₂O) δ 3.85 – 3.70 (s, 2H), 2.24 – 0.93 (m, 6H).

Acetic acid MVK polymer (9). O-(Carboxymethyl)hydroxylamine hemihydrochloride was conjugated to polymer 1 to afford polymer 9 as a white solid (0.5 mg, 25%). Conversion (NMR) = 0.83; Mₙ (NMR) = 58 kDa; ¹H NMR (500 MHz, D₂O) δ 3.85 – 3.70 (s, 2H), 2.24 – 0.93 (m, 6H).
Glycerol MVK polymer (10). 3-aminoxy-1,2-propanediol 14 was conjugated to polymer 1 to afford polymer 9 as a white solid (1 mg, 44%). Conversion (NMR) = 0.8; M_n (NMR) = 56 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 4.21 – 3.84 (m, 3H), 3.74 – 3.49 (m, 2H), 2.24 – 0.80 (m, 7H).

Alexa Fluor 488 N-acetylneuraminic acid-α2,6-galactose-β1,4-N-acetylglucosamine (AF488-2,6-SiaLacNAc) MVK copolymer (15). Polymer 1 was reacted with aminoxy 2,6SiaLacNAc and AO-AF488 to give polymer 15 as a green solid (3.1 mg, 81%). Conversion (NMR) = 0.83; M_n (NMR) = 219 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 5.03 – 4.87 (m, 1H), 4.47 – 4.34 (m, 1H), 4.03 – 3.37 (m, 19H), 2.77 – 2.63 (m, 1H), 2.00 (s, 3H), 1.74 – 1.69 (m, 1H), 2.29 – 1.10 (m, 7H).

Alexa Fluor 488 N-acetylneuraminic acid-α2,6-galactose-β1,4-N-acetylglucosamine (AF488-2,6-SiaLacNAc) MVK no lipid copolymer (16). Polymer 1 with an N-methyl tail instead of DPPE\(^6\) was reacted with aminoxy 2,6SiaLacNAc\(^4\) and AO-AF488 to give polymer 16 as a green solid (1.2 mg, 55%). Conversion (NMR) = 0.83; M_n (NMR) = 219 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 4.98 – 4.82 (m, 1H), 4.40 (d, J = 7.3 Hz, 1H), 4.13 – 3.38 (m, 18H), 2.68 (d, J = 10.1 Hz, 1H), 2.00 (s, 3H), 2.38 – 0.60 (m, 6H), 1.77 – 1.67 (m, 1H).

Alexa Fluor 488 N-acetylneuraminic acid (AF488-Sia) MVK copolymer (17). Polymer 17 was given from reaction of polymer 1 with aminoxy sialic acid 11 and AO-AF488 as a green solid (0.9 mg, 58%). Conversion (NMR) = 0.6; M_n (NMR) = 102 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 3.99 – 3.38 (m, 7H), 2.69 – 2.57 (m, 1H), 1.99 (s, 3H), 2.32 – 0.43 (m, 11H), 1.26 – 1.16 (m, 1H).

Alexa Fluor 488 N-acetylneuraminic acid-α2,8-N-acetylneuraminic acid-α2,3-galactose-β1,4-glucose (AF488-GD3) MVK copolymer (18). Polymer 18 was given from reaction of polymer 1 with aminoxy GD3 13 and AO-AF488 as a green solid (2.4 mg, 59%). Conversion (NMR) = 0.8; M_n (NMR) = 305 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 4.46 (d, J = 22.2 Hz, 1H), 4.18 – 3.47 (m, 29H), 2.74 (d, J = 9.3 Hz, 1H), 2.63 (d, J = 12.1 Hz, 1H), 2.01 (s, 3H), 1.98 (s, 3H), 2.37 – 0.75 (m, 7H), 1.72 – 1.66 (m, 1H).

Alexa Fluor 488 N-acetylgalactosamine (AF488-Lac) MVK copolymer (19). Aminoxy lactose\(^7\) and AO-AF488 were conjugated to polymer 1 to afford polymer 19 as a green solid (3.1 mg, 76%). Conversion (NMR) = 0.65; M_n (NMR) = 118 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 5.04 – 4.83 (m, 1H), 4.51 – 4.31 (m, 1H), 4.14 – 3.13 (m, 12H), 2.49 – 1.05 (m, 9H).

Biotin Galactose-β1,4-glucose (Lactose) MVK copolymer (20). Aminoxy lactose\(^4\) and AO-biotin were conjugated to polymer 1 to afford polymer 20 as a white solid (3.8 mg, 55%). Conversion (NMR) = 0.6; M_n (NMR) = 112 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 5.07 – 4.85 (m, 1H), 4.50 – 4.32 (m, 1H), 4.03 – 3.36 (m, 12H), 2.41 – 1.07 (m, 10H).

Biotin N-acetylgalactosamine (GalNAc) MVK copolymer (21). Aminoxy GalNAc\(^5\) and AO-biotin were conjugated to polymer 1 to afford polymer 21 as a white solid (0.8 mg, 16%). Conversion (NMR) = 0.75; M_n (NMR) = 98 kDa; \(^1\)H NMR (500 MHz, D_2O) δ 5.54 – 5.14 (m, 1H), 4.36 – 4.13 (m, 1H), 4.13 – 3.42 (m, 5H), 2.01 (s, 3H), 2.39 – 0.74 (m, 8H).
References cited

1. Ikehara, Y., Ikehara, S. K. & Paulson, J. C. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. *J. Biol. Chem.* **279**, 43117–43125 (2004).
2. Chen, X., Trivedi, P. P., Ge, B., Krzewski, K. & Strominger, J. L. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 6329–6334 (2007).
3. Cao, S., Tropper, F. D. & Roy, R. Stereoselective phase transfer catalyzed syntheses of glycosylxyosuccinimides and their transformations into glycoprobes. *Tetrahedron* **51**, 6679–6686 (1995).
4. Hudak, J. E., Yu, H. H. & Bertozzi, C. R. Protein Glycoengineering Enabled by the Versatile Synthesis of Aminooxy Glycans and the Genetically Encoded Aldehyde Tag. *J. Am. Chem. Soc.* **133**, 16127–16135 (2011).
5. Rabuka, D. *et al.* Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers. *J. Am. Chem. Soc.* **129**, 5462–5471 (2007).
6. Marcaurelle, L. A., Shin, Y., Goon, S. & Bertozzi, C. R. Synthesis of Oxime-Linked Mucin Mimics Containing the Tumor-Related TN and Sialyl TN Antigens. *Org. Lett.* **3**, 3691–3694 (2001).
Supplementary Note 2

Full immunoblots used to create indicated Figures

Full blots for Fig. 3c

Full blots for Fig. 3e
Full blots for Fig. 5b

anti-SHP1 rAb

anti-pY PY4G10

anti-FLAG-HRP